Researchers at Albert Einstein College of Medicine, New York found that 'glioblastoma', the deadliest brain cancer, can erode skull bones, alter marrow, and disrupt immunity. The study, published in 'Nature Neuroscience', revealed that anti-bone-loss drugs worsened tumour growth, offering new insight into why glioblastoma resists treatment and pointing toward better future therapies.